Digitala Vetenskapliga Arkivet

Planned maintenance
A system upgrade is planned for 17/11-2026, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Chemoradiation therapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer: mature results of the ARTSCAN III trial
Department of Hematology, Oncology and Radiation Physics, Department of Clinical Sciences Lund, Division of Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Department of Hematology, Oncology and Radiation Physics, Department of Clinical Sciences Lund, Division of Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Department of Hematology, Oncology and Radiation Physics, Department of Clinical Sciences Lund, Division of Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
Show others and affiliations
2025 (English)In: International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, E-ISSN 1879-355X, Vol. 123, no 3, p. 681-690Article in journal (Refereed) Published
Abstract [en]

Purpose: The study investigated curative radiation therapy (RT) plus cisplatin versus RT plus cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).

Methods and Materials: This was a Swedish multicenter randomized phase 3 study. Included patients were randomized 1:1. Patients with T3-T4 tumors underwent a second randomization 1:1 between a final RT dose of 68.0 and 73.1 Gy to the primary tumor. Cisplatin dosage was 40 mg/m2/wk during RT. Cetuximab was administered with a loading dose of 400 mg/m2 1 week before start of RT, followed by weekly doses of 250 mg/m2 during RT. Primary endpoint was overall survival (OS), evaluated by adjusted Cox regression analysis. Secondary endpoints were locoregional control, pattern of failure, morbidity, quality of life (QL), and comparisons between dose-escalated RT and standard-dose RT in T3-T4 tumors.

Results: Following an unplanned interim analysis, patient inclusion was prematurely closed. The intention-to-treat population included 291 patients, 76% of whom had p16-positive oropharyngeal cancer. Median follow-up was 7.5 years for OS and 5.3 years for treatment efficacy. Five-year OS was 82% (95% confidence interval [CI], 76-89) in the RT plus cisplatin group compared with 71% (95% CI, 64-79) in the RT plus cetuximab group (log-rank P = .019). Adjusted hazard ratios for OS, locoregional failure, and distant failure were 1.66 (95% CI, 1.08−2.56; P = .021), 2.24 (95% CI, 1.25-4.02; P = .007), and 1.44 (95% CI, 0.67-3.09; P = .34), respectively, for patients treated with concomitant cetuximab versus cisplatin. Although potentially affected by the early termination of patient inclusion, no improvement in local control was found in patients with T3-T4 tumors receiving RT dose escalation (adjusted HR, 0.63; 95% CI, 0.30-1.34; P = .23). Late morbidity and QL were similar between the treatment groups.

Conclusions: The study showed inferior treatment outcomes for cetuximab compared with cisplatin concurrent with RT. Cisplatin remains standard concomitant treatment for locoregionally advanced HNSCC.

Place, publisher, year, edition, pages
Elsevier, 2025. Vol. 123, no 3, p. 681-690
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-242301DOI: 10.1016/j.ijrobp.2025.05.086PubMedID: 40543675Scopus ID: 2-s2.0-105010322294OAI: oai:DiVA.org:umu-242301DiVA, id: diva2:1985066
Available from: 2025-07-21 Created: 2025-07-21 Last updated: 2025-09-23Bibliographically approved

Open Access in DiVA

fulltext(330 kB)102 downloads
File information
File name FULLTEXT02.pdfFile size 330 kBChecksum SHA-512
ae012692fc9e6c78512c79f3061f25bf42d189c20a58e23c34d2fb9bd69ca94c0fddeee1217297ececb67f642ed91539df1706a06fe771373b870da8b05f0fcc
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Söderkvist, KarinThomasson, MarcusZackrisson, Björn
By organisation
Department of Diagnostics and Intervention
In the same journal
International Journal of Radiation Oncology, Biology, Physics
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 146 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 473 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf